Mathematical modelling of breast cancer cells in response to endocrine therapy and Cdk4/6 inhibition

Simple item page
dc.contributor.authorHe, Weien
dc.contributor.authorDemas, Diane M.en
dc.contributor.authorConde, Isabel P.en
dc.contributor.authorShajahan-Haq, Ayesha N.en
dc.contributor.authorBaumann, William T.en
dc.contributor.departmentElectrical and Computer Engineeringen
dc.date.accessioned2020-12-15T13:52:08Zen
dc.date.available2020-12-15T13:52:08Zen
dc.date.issued2020-08-26en
dc.description.abstractOestrogen receptor (ER)-positive breast cancer is responsive to a number of targeted therapies used clinically. Unfortunately, the continuous application of any targeted therapy often results in resistance to the therapy. Our ultimate goal is to use mathematical modelling to optimize alternating therapies that not only decrease proliferation but also stave off resistance. Toward this end, we measured levels of key proteins and proliferation over a 7-day time course in ER+ MCF-7 breast cancer cells. Treatments included endocrine therapy, either oestrogen deprivation, which mimics the effects of an aromatase inhibitor, or fulvestrant, an ER degrader. These data were used to calibrate a mathematical model based on key interactions between ER signalling and the cell cycle. We show that the calibrated model is capable of predicting the combination treatment of fulvestrant and oestrogen deprivation. Further, we show that we can add a new drug, palbociclib, to the model by measuring only two key proteins, cMyc and hyperphosphorylated RB1, and adjusting only parameters associated with the drug. The model is then able to predict the combination treatment of oestrogen deprivation and palbociclib. We illustrate the model's potential to explore protocols that limit proliferation and hold off resistance by not depending on any one therapy.en
dc.description.notesThis work was partly supported by Public Health Service grant R01-CA201092 to W.T.B. and A.N.S.-H. Technical services were provided by shared resources at Georgetown University Medical Center, including the Tissue Culture Core Shared Resource, that were funded through Public Health Service award 1P30-CA-51008 (Lombardi Comprehensive Cancer Center Support Grant).en
dc.description.sponsorshipPublic Health Service grantUnited States Public Health Service [R01-CA201092, 1P30-CA-51008]en
dc.format.mimetypeapplication/pdfen
dc.identifier.doihttps://doi.org/10.1098/rsif.2020.0339en
dc.identifier.eissn1742-5662en
dc.identifier.issn1742-5689en
dc.identifier.issue169en
dc.identifier.other20200339en
dc.identifier.pmid32842890en
dc.identifier.urihttp://hdl.handle.net/10919/101350en
dc.identifier.volume17en
dc.language.isoenen
dc.rightsCreative Commons Attribution 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.subjectmathematical modellingen
dc.subjectbreast canceren
dc.subjecttherapy optimizationen
dc.subjectendocrine therapyen
dc.subjectpalbocicliben
dc.titleMathematical modelling of breast cancer cells in response to endocrine therapy and Cdk4/6 inhibitionen
dc.title.serialJournal of The Royal Society Interfaceen
dc.typeArticle - Refereeden
dc.type.dcmitypeTexten
dc.type.dcmitypeStillImageen

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
rsif.2020.0339.pdf
Size:
1.63 MB
Format:
Adobe Portable Document Format
Description:
Download

Collections

Scholarly Works, Electrical and Computer Engineering
Graduate Student Papers